Diagnostic and Life Science Equipment Stocks Surge... Market Cap Increased by Nearly 900 Billion Won in One Day

Revvity Inc., a U.S. diagnostics and life-sciences equipment company, jumped 5.68% on the New York Stock Exchange on the 28th, closing at $102.29. Its market capitalization climbed to about $11.4 billion—roughly KRW 15 trillion—adding nearly $690 million (approximately KRW 900 billion) in a single day. Investors drove the rally after the company’s strong first-quarter results and renewed hopes for restructuring announced earlier this month.

On May 5, Revvity reported 3% organic revenue growth for Q1 and delivered adjusted EPS of $1.06, beating analysts’ forecasts. The company also revealed plans to sell its lower-growth China immunodiagnostics business. In January, Revvity’s board approved a quarterly dividend of $0.07 per share, with the first payment completed on May 8, underscoring its commitment to shareholder returns.

Spun off from PerkinElmer’s life sciences and diagnostics division in 2023, Revvity supplies reagents, instrumentation, and software to pharmaceutical and biotech companies, diagnostic laboratories, academic institutions, and government agencies. In 2024 it generated about $2.7 billion in revenue (roughly KRW 3.6 trillion), employs around 11,000 people, and is a constituent of the S&P 500 index.